Good Pharmacovigilance Practice (GPvP) in the United Kingdom

1. Overview and Purpose

Good Pharmacovigilance Practice (GPvP) is the minimum standard for monitoring the safety of medicines on sale to the public in the UK. It sets out the essential framework that marketing authorisation holders (MAHs) must apply to ensure robust pharmacovigilance systems are in place.
Source: Good pharmacovigilance practice (GPvP) (gov.uk)

GPvP helps ensure that risks associated with medicinal products are properly detected, assessed, and prevented where possible, supporting the protection of public health through ongoing safety monitoring. It applies across all authorised human medicines marketed in the UK.
Source: Good pharmacovigilance practice (GPvP) (gov.uk)

2. Pharmacovigilance System Requirements

Under GPvP, MAHs must establish and maintain a pharmacovigilance system capable of systematically collecting, monitoring, and evaluating safety information about their medicines. This includes operational structures and procedures for adverse event reporting and safety signal detection.
Source: Good pharmacovigilance practice (GPvP) (gov.uk)

Key elements include:

• A qualitatively robust approach to identifying and analysing suspected adverse reactions.
• Procedures for prompt reporting of safety information to the UK licensing authority (MHRA) or relevant repository.
• Maintenance of records and documentation to support regulatory compliance and inspections.
  Source: Pharmacovigilance requirements: qualified person for PV (gov.uk)

3. Qualified Person Responsible for Pharmacovigilance (QPPV)

One of the core responsibilities under GPvP is the appointment of a Qualified Person Responsible for Pharmacovigilance (QPPV). The QPPV is responsible for establishing and maintaining the pharmacovigilance system for UK authorised products, and ensuring that safety reporting obligations are met.
Source: Pharmacovigilance requirements: qualified person for PV (gov.uk)

The QPPV must be appropriately qualified, with authority to influence safety activities and access to necessary data, and must reside or operate within the UK.
Source: Pharmacovigilance requirements: qualified person for PV (gov.uk)

4. Pharmacovigilance System Master File (PSMF)

MAHs must establish a Pharmacovigilance System Master File (PSMF) that comprehensively describes their pharmacovigilance system and activities. The PSMF supports regulatory oversight and should be readily accessible for inspection by the Medicines and Healthcare products Regulatory Agency (MHRA).
Source: Pharmacovigilance requirements: qualified person for PV (gov.uk)

The PSMF includes organisational structures, procedures, quality systems, and details on data sources and reporting mechanisms, tailored to UK regulatory requirements.
Source: Pharmacovigilance requirements: qualified person for PV (gov.uk)

5. Reporting and Risk Management

GPvP mandates that MAHs have processes to:

• Collect and evaluate safety data from multiple sources, including spontaneous reports, clinical trials, and scientific literature.
• Detect and assess safety signals that may indicate emerging risks.
• Report relevant safety information to the MHRA in accordance with statutory timelines.
  Source: Guidance on pharmacovigilance procedures (gov.uk)

GPvP aligns with broader pharmacovigilance procedures that outline the submission of individual case safety reports (ICSRs), Periodic Safety Update Reports (PSURs), and risk management plans.
Source: Guidance on pharmacovigilance procedures (gov.uk)

6. Inspections and Compliance

The MHRA conducts inspections of pharmacovigilance systems to verify compliance with GPvP standards. Inspection metrics and outcomes provide insight into common compliance issues and areas for improvement.
Source: Good pharmacovigilance practice - MHRA Inspectorate (gov.uk)

Non-compliance with GPvP can lead to regulatory action, including enforcement measures to protect public health.
Source: Good pharmacovigilance practice (GPvP) (gov.uk)

7. Practical Significance

Good Pharmacovigilance Practice ensures that safety information is systematically managed and acted upon throughout a medicinal product’s lifecycle. It safeguards that potential risks are identified early and addressed appropriately, contributing to safer use of medicines by patients.
Source: Good pharmacovigilance practice (GPvP) (gov.uk)

Conclusion

GPvP sets the foundation for effective pharmacovigilance in the UK, integrating organisational requirements, reporting responsibilities, and regulatory oversight to maintain medicine safety post-authorisation.
Source: Good pharmacovigilance practice (GPvP) (gov.uk)